Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.

Authors:
Dr  Sameer Rastogi, MD, DM Medical Oncology
Dr Sameer Rastogi, MD, DM Medical Oncology
All India Institute of Medical Sciences
Assistant Professor
Medical Oncology (Sarcoma)
Delhi | India

Future Oncol 2015 ;11(8):1191-200

Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, India.

Background: Gemcitabine-platinum (Gem-P) is the current standard for patients with advanced gall bladder cancer.

Materials & Methods: This is retrospective analysis of a prospectively maintained database of 210 patients with advanced gall bladder cancer treated with Gem-P between January 2012 and September 2013.

Results: Median age was 53 years, 65.2% females. In total,158 patients had metastatic and 52 had locoregional disease. Median number of cycles was 5 (1-12). At a median follow-up of 10 months, median overall survival/progression-free survival was 10/5 months, respectively. On multivariate analysis, patients who underwent prior surgery for primary and locoregional disease had a significantly better progression-free survival and those with locoregional disease had a significantly better overall survival. A total of 45.7% received second-line chemotherapy.

Conclusion: Use of Gem-P in Indian patients leads to slightly worse outcomes suggesting an aggressive biology.

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.295DOI Listing
February 2016
58 Reads
4 Citations
2.480 Impact Factor

Publication Analysis

Top Keywords

advanced gall
12
gall bladder
12
locoregional disease
12
patients advanced
12
bladder cancer
8
indian patients
8
disease better
8
patients
6
months median
4
follow-up months
4
median follow-up
4
median survival/progression-free
4
survival 10/5
4
multivariate analysis
4
months multivariate
4
10/5 months
4
1-12 median
4
survival/progression-free survival
4
disease median
4
females total158
4

References

(Supplied by CrossRef)

Leal LJ et al.
J. Clin. Oncol. 2014

Similar Publications